Longitude beats 'brutal' conditions as new life science fund exceeds target

After reporting in September that it raised $331.6 million of a $375 million venture capital fund, Menlo Park, California-based Longitude Capital announced on 10 October that it closed Longitude Venture Partners II with $385 million to invest in drug development and medical technology.

After reporting in September that it raised $331.6 million of a $375 million venture capital fund, Menlo Park, California-based Longitude Capital announced on 10 October that it closed Longitude Venture Partners II with $385 million to invest in drug development and medical technology.

Longitude Capital co-founder and managing director Patrick Enright told Scrip last month that the fundraising environment for life science-focused venture...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip